Retrophin plots a $40M IPO amid a spree of deals

It's been a busy month for Retrophin ($RTRX), and CEO Martin Shkreli is capping it off with an IPO filing, looking to take his company from over-the-counter trading to the Nasdaq and pick up $40 million in the process. The biotech recently traded $5 million for Novartis' ($NVS) oxytocin nasal spray with hopes of developing the long-shelved drug into a treatment for schizophrenia and autism, a move that grabbed headlines--though many of them boiled down to "Is Retrophin for real?" The company's pipeline also includes a Phase II treatment for focal segmental glomerulosclerosis and early stage drugs targeting nephrotic syndrome, infantile spasms and neurodegeneration. Filing

Suggested Articles

IBM and Pfizer developed an artificial intelligence model that could eventually predict if a person will develop Alzheimer’s using a language test.

After teaming up with other Big Pharmas to bolster antibiotics research, Pfizer is adding a new antibiotic prospect to its pipeline.

The oral direct-acting antiviral is set to enter a phase 3 trial in non-hospitalized patients early next year.